Halaman 3 - Imunoterapi Dokter Terbaik - TOP-85 dokter

Profesor Madya Tahsin Ozatli berspesialisasi dalam kanker payudara, paru-paru, dan saluran cerna di Rumah Sakit Universitas Istinye Liv.

• Pengalaman lebih dari satu dekade dalam bidang onkologi
• Pernah bekerja di Klinik Onkologi Ankara dan Rumah Sakit Pelatihan dan Penelitian Regional Erzurum
• Dipromosikan menjadi Profesor Madya pada tahun 2016
• Menempuh studi kedokteran di Universitas Selcuk

Kepala Dokter di pusat kanker bersertifikat BKZ Solingen – Dr. Fox berspesialisasi dalam imunoterapi dan diagnostik molekuler untuk penyakit tumor.

• 15+ tahun sebagai ahli hematologi, onkologi, dan imunologi
• Ahli dalam penelitian biologi molekuler untuk penyakit hemato-onkologi
• Anggota masyarakat onkologi Jerman dan Amerika
• Berspesialisasi dalam terapi target di samping imunoterapi

Dr. Ozden berspesialisasi dalam onkologi medis dengan pengalaman lebih dari 20 tahun di bidang penyakit dalam dan onkologi.

• Menyelesaikan subspesialisasi onkologi medis di Fakultas Kedokteran Universitas Kocaeli
• Mempraktikkan penyakit dalam di berbagai rumah sakit di Turki
• Lulus dari Fakultas Kedokteran Cerrahpaşa Universitas Istanbul

Dr. Alemdar berspesialisasi dalam onkologi medis dengan pelatihan ekstensif di Universitas Akdeniz – pemimpin dalam penelitian kanker.

• Tersertifikasi dewan dalam onkologi medis sejak 2018
• Praktik di Medical Park Antalya Hospital Complex
• Pengalaman lebih dari 15 tahun di bidang penyakit dalam dan onkologi
• Terlatih di Universitas Akdeniz – pusat penelitian kanker terkemuka di Turki

Dr. Salman berspesialisasi dalam imunoterapi untuk berbagai kanker, mengintegrasikan terapi bertarget dan vaksin kanker. Dia menempuh pelatihan di institusi bergengsi seperti Memorial Sloan Kettering Cancer Center.

• Associate Professor di Universitas Katip Çelebi dengan pengalaman 7+ tahun dalam onkologi medis
• Pengunjung akademik di Moffitt Cancer Center di Florida, AS
• Anggota dewan Turkish Society of Medical Oncology dan European Society of Medical Oncology
• Menggunakan pembuatan profil genomik komprehensif untuk rencana perawatan yang dipersonalisasi
• Aktif dalam penelitian klinis dan terapi medis eksperimental

Profesor Onkologi Medis dengan pengalaman lebih dari 20 tahun, berspesialisasi dalam pengobatan kanker stadium lanjut di İstinye University Liv Hospital Topkapı.

• Lulusan program *Fellowship* dalam Onkologi Medis di Universitas Trakya
• Profesor Madya dan kemudian Profesor di Fakultas Kedokteran Universitas Trakya
• Anggota Asosiasi Onkologi Medis Turki

Prof. Madya Nail Paksoy berspesialisasi dalam imunoterapi di Rumah Sakit Medipol Bahçelievler, dengan latar belakang kuat dalam onkologi medis dan alergi-imunologi.

• Bersertifikasi Dewan ESMO dalam Onkologi Medis
• Berpartisipasi dalam 8 uji klinis internasional untuk imunoterapi
• Menerbitkan beberapa studi tentang hasil pengobatan kanker
• Pelatihan Fellowship di Institut Onkologi Universitas Istanbul

Dr. Eckhart Weidmann memimpin sektor Hematologi di Klinik Nordwest, berspesialisasi dalam pengobatan kelainan darah dengan pengalaman praktik lebih dari 30 tahun.

• Salah satu dokter terbaik untuk limfoma non-Hodgkin
• Profesor dengan keahlian akademik dan klinis yang luas
• Fokus pada imunoterapi untuk kelainan darah

Profesor Madya Atakan Topcu berspesialisasi dalam imunoterapi dan terapi target untuk tumor padat di Rumah Sakit Distrik Medipol Acibadem.

• Telah mempublikasikan lebih dari 50 artikel ilmiah di bidang onkologi
• Anggota Masyarakat Eropa untuk Onkologi Medis (ESMO)
• Pakar dalam onkologi geriatri dan malnutrisi terkait kanker
• Memiliki pelatihan fellowship dalam onkologi medis di Universitas Bezmialem Vakıf

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Profesor Madya Onkologi Medis di İstinye University Liv Hospital Topkapı – berspesialisasi dalam imunoterapi untuk pengobatan kanker.

• 10+ tahun pengalaman dalam onkologi medis
• Anggota American Society of Clinical Oncology (ASCO)
• Telah mempublikasikan berbagai artikel tinjauan sejawat mengenai hasil pengobatan kanker
• Fokus pada imunoterapi untuk berbagai jenis kanker

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.

She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.

She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.